Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

NCT04688151 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma (PCNSL)

Interventions

DRUG: Rituximab

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]